ArticleEndocrine, metabolic & immune disorders drug targets2026
Akkermansia muciniphila Delays the Progression of Diabetic Nephropathy by Reducing the Accumulation of Uremic Toxins in the Feces and Peripheral Blood
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of pasteurizedGut microbes · 2026Trial
- Gut microbiota-liver-kidney axis in diabetic kidney disease: mechanistic insights into amino acid metabolism and nutritional intervention strategies targeting natural bioactive compounds.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathogenesis of diabetes and diabetic kidney disease (DKD) is closely related to the imbalance of gut microbiota. We aimed to explore whether exogenous Akkermansia muciniphila (A. muciniphila) supplementation affected the progression of DKD.
methodsThe feces from normal subjects, diabetic patients without kidney diseases, and patients with DKD were collected, and the changes in microbial communities were analyzed. A rodent db/db DKD model was also constructed to investigate whether the abundance of A. muciniphila would be altered in response to renal function decline. The measurement of inflammatory cytokines in peripheral blood, fecal short-chain fatty acids (SCFAs), renal histopathology, and Western blot analysis were carried out to further evaluate the effects of A. muciniphila.
resultsThe relative abundance of A. muciniphila was found to be lower in the feces of DKD patients and also in the intestine of DKD mice. After exogenous supplementation of A. muciniphila, the levels of urinary protein, blood urea nitrogen, and creatinine decreased in DKD mice, as well as uremic toxins, trimethylamine-N-oxide (TMAO), p-cresol sulfonate, and indole sulfonate. A. muciniphila supplementation also increased the SCFAs gut production. The supplementation also protected the integrity of the intestinal mucosa by increasing MUC2, occludin, and zona occludens 1 (ZO-1) protein expression in the intestinal wall.
conclusionExogenous supplementation of A. muciniphila improved the imbalance of gut microbiota, reduced systemic inflammation, decreased uremic toxins, and protected the integrity of the intestinal mucosa, thus delaying DKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.